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SUMMARY  1 
Aims AT9283 is used to treat patients with solid tumors and patients with leukaemia. However, 2 
the maximum tolerated dose (MTD) for children with leukaemia remains unknown due to early 3 
termination of the Phase I trial.  The aim of this study was to develop a population model of 4 
AT9283 to describe the pharmacokinetics in adults and children and to estimate the MTD in 5 
children with leukaemia. 6 
Methods Data from Phase I dose-escalation studies in adults and children were used to build a 7 
population pharmacokinetic model (NONMEM v7.3). Potential covariates investigated included 8 
body weight, body surface area (BSA), glomerular filtration rate (GFR), age and sex. Model-9 
derived AUC was used to investigate the relationship between dose and exposure in adults and 10 
children. 11 
Results The plasma concentrations of AT9283 (n = 1770) from 92 patients (53 adults, 39 12 
children) were used to build a two-compartment model with all pharmacokinetic parameters 13 
scaled using body weight. Renal function (GFR), but not BSA, was a significant covariate for the 14 
clearance of AT9283.  In children with leukaemia (median weight 16 kg), a flat dose of 500 15 
mg/72 h provided similar drug exposures at the MTD as the adult population. The estimated 16 
MTD for children with leukaemia, therefore, is 30 mg/kg/72 h.  17 
Conclusion For adults, GFR was a significant predictor of CL, whilst body-weight based dosing 18 
was more useful than BSA in determining the drug exposure in children. The MTD was 19 
estimated to be 30 mg/kg/72 h children with leukaemia. 20 
  21 
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 1 
• Adults with leukaemia can tolerate a 10-fold higher dose of AT9283 than adults with 2 
solid tumors. 3 
• AT9283 is dosed by body surface area (BSA) but other factors influencing the 4 
pharmacokinetics of AT9283 were not investigated 5 
• The maximum tolerated dose (MTD) of AT9283 in children with leukaemia is not 6 
known. 7 
WHAT THIS STUDY ADDS 8 
• A population pharmacokinetic model was used to combine the adult and children studies 9 
to investigate factors that may influence the pharmacokinetics of AT9283. 10 
• GFR and body weight are better predictors of clearance than BSA  11 
• Doses of  30 mg/kg/72h in children with leukaemia would provide similar exposure 12 
levels to that seen in adults with leukaemia at the maximum tolerated doses (MTD). 13 
 14 
  15 
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1. INTRODUCTION 1 
 2 
The Aurora kinases (A, B and C) play a critical role in the cell mitotic process [1, 2].  Aurora 3 
Kinase A is involved in centrosome function, mitotic entry and spindle assembly, whilst Aurora 4 
Kinase B is a chromosomal passenger protein and is involved in chromatin modification, 5 
microtubule-kinetochore attachment, spindle checkpoint and cytokinesis [1, 3]. Aurora Kinase C 6 
is also a chromosomal passenger protein, and exhibits similar functions to Aurora Kinase B [3]. 7 
Aurora kinases are overexpressed in many cancers, therefore aurora kinase inhibitors are 8 
promising anticancer drugs. Aurora kinase inhibitors may be particularly useful against 9 
hematologic malignancies due to greater genetic homogeneity and greater proliferations rates 10 
relative to solid tumours [4, 5]. 11 
 12 
AT9283 (Astex Pharmaceuticals®) is a multi-targeted aurora kinase inhibitor found to be 13 
a potent inhibitor of Aurora A, Aurora B and other kinases including JAK2, FLT3 and Abl 14 
(T315I) [6].  In adults and children with solid tumours, AT9283 demonstrated significant aurora 15 
kinase inhibition at tolerable doses with disease stabilization [4, 7]. However, the use of AT9283 16 
is limited by its toxicity profile.  Some of these dose-limiting toxicities (DLTs) included 17 
neutropenia (grade 3-4), tumor lysis syndrome, bacterial infections cardiovascular and 18 
gastrointestinal disorders [4, 7, 8]. 19 
AT9283 is administered as a continuous 72-hour infusion and is dosed by body surface 20 
area (BSA). In Phase I studies of AT9283, the maximum tolerated dose (MTD) was identified 21 
for adults with solid tumors (27 mg/m2/72h) [7], adults with leukaemia (324 mg/m2/72h) [8] and 22 
for children with solid tumors (55.5 mg/m2/72h) [4]. The Phase I study for children with 23 
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leukaemia, however, was terminated due to a slow recruitment rate. Only seven children were 1 
recruited in this study and the maximum dose level reached was 69 mg/m2/72h. 2 
The pharmacokinetics of AT9283 was previously investigated using a non-3 
compartmental approach in each population group [4, 7, 8]. Each pharmacokinetic study noted 4 
large inter-individual variability (IIV) in the pharmacokinetics of AT9283, even after adjusting 5 
doses for BSA [4]. Furthermore, the increase in exposure to AT9283 was proportional to 6 
absolute administered dose, rather than the BSA-based dosing level [4]. A better understanding 7 
of the relationship between AT9283 doses and plasma concentration, as well as determinants of 8 
drug exposure, will enable doses of AT9283 to be optimized for each patient population. 9 
 10 
Population pharmacokinetic modelling and simulation is an industry standard method of 11 
investigating the pharmacokinetics of a drug to identify measurable pathophysiological factors 12 
influencing the pharmacokinetics of the drug [9]. In this study, the data from adult and children 13 
studies were pooled to describe the pharmacokinetics in these population groups. Furthermore, 14 
this population model was used to simulate doses in children with leukaemia and to estimate 15 
what the MTD would be in this population. 16 
 17 
2. METHODS 18 
 19 
2.1 Datasets and study design 20 
Phase I data for this investigation originated from four separate pharmacokinetic studies in adults 21 
([7, 8]; NCT00443976, NCT00522990) and children ([4]; NCT0098568, NCT01431664) and 22 
were sponsored by Astex Pharmaceuticals and Cancer Research UK., respectively. These dose-23 
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escalation studies were designed to investigate the safety and tolerability of AT9283 in each 1 
population group and to establish a dose for Phase II studies (Table 1). The conventional 3 + 3 2 
study design was used for the adults (solid tumor and leukaemia) and children with leukaemia, 3 
whilst the rolling six design was used for children with solid tumors.   4 
Written informed consent was obtained from all patients and from all parents and guardians of 5 
children. These studies were approved by the local ethics committees for each trial centre 6 
(various locations in the U.S. and the U. K.) [4, 7, 8, 10] and were conducted to Good Clinical 7 
Practice in accordance with the Declaration of Helsinki and its amendments. 8 
 9 
2.2 AT9283 dosing 10 
AT9283 was administered as a continuous three-day (72 h) i.v. infusion every 21 days via central 11 
venous access. The doses of AT9283 were adjusted according to body surface area (BSA), which 12 
was calculated using the Mosteller formula [11]. The maximum tolerated dose (MTD) was 13 
defined as the highest dose that could be given based on the incidence of dose-limiting toxicities 14 
(DLTs). For the 3 + 3 design, the MTD was defined as the dose given to three patients with less 15 
than one patient experiencing a DLT. For the rolling six design, the MTD is the dose given to six 16 
patients with less than one patient experiencing a DLT.  17 
 18 
2.3 AT9283 concentrations 19 
Blood samples for pharmacokinetic analyses were collected during the first and second cycle for 20 
the adult studies and during the first cycle for studies conducted in children. The time-points for 21 
blood collection are outlined in Table 1. The concentrations of AT9283 were quantified using a 22 
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validated LC-MS/MS assay [4] (Astex Investigator’s Brochure) over a calibration range of 0.1 – 1 
500 ng/mL. The lower limit of quantification (LLOQ) was 0.1 ng/mL.  2 
 3 
2.4 Population modelling 4 
Population pharmacokinetic analyses were conducted using the population modelling package 5 
NONMEM® 7.3.0 (ICON Development Solutions, Hanover, MD, USA) [12] with first-order 6 
conditional estimation method with interaction (FOCE-I). Model development was managed 7 
using Perl-Speaks-NONMEM 3.5.3 [13], Pirana 2.8.1[14] and R (Version 3.2.5) [15]. Model 8 
selection was informed by using the objective function value (OFV, -2log likelihood) [16],  9 
whereby a reduction of >3.84 points in OFV was considered statistically significant (P <0.05 10 
with d.f. = 1, approximate asymptotic 𝑥"-distribution).  11 
 12 
2.4.1 Structural and statistical model 13 
The pharmacokinetics of AT9283 was tested using one-compartment and two-compartment 14 
structural models. The inter-individual variability (IIV) is the unexplained random variability 15 
between individuals, which was described using a log-normal distribution (Eq. 1): 16 𝑃$ 	= 	𝑃'(	 ×	𝑒𝑥𝑝(-.)                                      (1)	17 
where Pi is the pharmacokinetic parameter of the ith individual. PTV is the typical population 18 
parameter value, ni is the IIV in the ith individual with a distribution of N(0, ωIIV2). 19 
Different error models were tested to describe the residual unexplained variability of the 20 
data (additive, proportional, mixed, exponential, log-transformation). A separate residual error 21 
model was also evaluated for each of the studies to account for variability in the assays. Only 3% 22 
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of the observations of the dataset were below the limit of quantification, and were therefore 1 
excluded from the analysis. 2 
 3 
 4 
2.4.2 Covariate model 5 
Potential covariates were evaluated by visual inspection of the empirical Bayes estimates (EBEs) 6 
against the covariates and by step-wise inclusion into the model. The covariates investigated 7 
included measurements of body size (body weight, BMI, lean body weight, BSA, fat-free mass 8 
[17]), cancer type and kidney function (glomerular filtration rate, GFR). The backward 9 
elimination of covariates was used to confirm covariate selection, whereby an increase in OFV 10 
(>6.63, P <0.01) was required. 11 
For continuous covariates, linear, piecewise-linear, exponential and power relationships were 12 
investigated. There were only two children aged under 2 years, therefore a model to describe CL 13 
maturation with age for children under 2 years was not needed. 14 
An allometric weight model was used to standardize all pharmacokinetic parameters to a body 15 
weight of 70 kg [18]. The allometric weight model for the clearance parameters and volume 16 
parameters are shown in Eq. 2 and 3, respectively. 17 
𝐹12 = 	 3 4'4'56789.;<              (2) 18 𝐹( = 3 4'4'5678=                   (3) 19 
Where a standard weight value of 70 kg (WTSTD) was used to normalize pharmacokinetic 20 
parameters in adults and children.  21 
For adults, GFR was estimated using the Modification of Diet in Renal Disease (MDRD) 22 
formula for adults [19] (Eq. 4):  23 
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𝐺𝐹𝑅	(𝑚𝐿/𝑚𝑖𝑛/1.73𝑚")1 = 	175	 × [𝑠𝑒𝑟𝑢𝑚	𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒	(𝜇𝑚𝑜𝑙/𝐿)]	T=.=<U × 𝐴𝑔𝑒	(𝑦𝑒𝑎𝑟𝑠)T9."9Y 	× 𝑘	2 
(4) 3 
where k is 1 for males and 0.742 for females. 4 
For children aged under 18 years, the bedside Schwartz formula [20] was used (Eq. 5): 5 
𝐺𝐹𝑅	(𝑚𝐿/𝑚𝑖𝑛/1.73𝑚") = 	 41.3	𝑥	ℎ𝑒𝑖𝑔ℎ𝑡	(𝑐𝑚)𝑠𝑒𝑟𝑢𝑚	𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒	(𝜇𝑚𝑜𝑙/𝐿) × 0.01131	6 
                  (5) 7 
2.4.3 Model evaluation 8 
The model was evaluated by visual inspection of goodness of fit plots of the observed and predicted 9 
concentrations and conditional weighted residuals (CWRES). The final model performance was 10 
examined by using prediction-corrected visual predictive checks (VPCs) to compare the 5th, 50th 11 
and 95th percentiles of the observed concentrations and simulations of concentration–time profiles 12 
(1,000 replicates) from the final model [21]. A nonparametric bootstrap method [22] (n = 1,000) 13 
was used to study the uncertainty of all pharmacokinetic parameter estimates in the final model to 14 
obtain the median and 95% confidence interval of the parameter estimates.  Significant differences 15 
between baseline measurements were evaluated using the unpaired t test in R. A P value of <0.05 16 
was considered statistically significant. 17 
 18 
2.5 AT9283 exposure 19 
The final model was used to calculate the area-under the curve (𝐴𝑈𝐶9T`)	of AT9283 using post-20 
hoc estimates of CL (𝐴𝑈𝐶9T` = Dose/CL). Using the final model, stochastic simulations were 21 
performed to simulate concentration-time profiles (n = 1,000) using the median dose and median 22 
BSA for patients who were administered the MTD dose. The concentrations of AT9283 at the 23 
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MTD were compared to investigate the variability in the drug exposure for the different patient 1 
groups.  2 
For children with leukaemia, dosing simulations were conducted to target a similar range of 3 𝐴𝑈𝐶9T` to that seen in adults with leukaemia. Since there were limited data for children with 4 
leukaemia, the exposure-toxicity relationship was assumed to be the same in adults and children. 5 
 6 
 7 
3. Results 8 
 9 
3.1 Study population 10 
A summary of the patient demographics is shown in Table 2. The dose administered ranged from 11 
4.5 mg/m2/72 h to 486 mg/m2/72h. For children with leukaemia, the trial was terminated at a 12 
dose of 69 mg/m2/72 h. About half of the adult population had mild to moderately reduced 13 
kidney function (GFR <90 mL/min/1.73m2), whilst children had predominately healthy kidney 14 
function (GFR > 100 mL/min/1.73m2) (Table 2, Supplementary Figure 1). Compared to children 15 
(GFR, 132.9 [47.4 – 299.4] mL/min/1.73m2, median [range]), most adults had some form of 16 
kidney dysfunction (GFR, 77.1 [31.9 – 170.5] mL/min/1.73m2; P <0.001). As expected, there 17 
was larger variability in the BSA in children than in adults. Children with leukaemia were 18 
younger (difference between the medians of 7 years, P <0.01) and had a smaller BSA (0.34 m2, 19 
P <0.001), compared to children with solid tumors. 20 
 21 
3.2 Population model 22 
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A total of 1770 observations from 92 individuals were used for population analyses. This dataset 1 
was best described using a two-compartment model. All observations were log-transformed and 2 
the residual variability was described using a combined additive and proportional error model for 3 
the adult population and an additive error model for children. The separate error model for the 4 
adults and children was used to account for site-specific variability in sample collection and the 5 
analytical assays (ΔOFV -118.1). The IIV was estimated on all parameters. The correlations 6 
between the IIV of each parameter was estimated using a full covariance matrix.  7 
 8 
The influence of body size on the pharmacokinetic parameters for adults and children 9 
was best described using an allometric model with body weight for CL. An empirical GFR 10 
power model was used to describe the effect of renal function on clearance, normalized to a 11 
standard of 6 L/h (100 mL/min), which significantly improved the model (ΔOFV -66.3, reduced 12 
IIV by 1.6%). There were no significant differences between the CL of AT9283 in patients with 13 
solid tumors (25.5 [9.0 – 66.7] L/h) and patients with leukaemia (27.8 [4.3 – 48.0] L/h, P = 14 
0.12). Cancer type was not a significant covariate in the model for any pharmacokinetic 15 
parameter (did not reduce the IIV). The final equations for CL and VC were (Eq. 6 and 7): 16 
𝐶𝐿 = 𝜃12 	×	3 4'4'56789.;< ×	3 bcdbcd5678efg             (6) 17 𝑉1 = 𝜃(1 	×	3 4'4'5678=               (7) 18 
Where 𝜃i1  is the estimated power parameter for GFR. 19 
 20 
The goodness-of-fit plots showed that the final model described the pharmacokinetics of AT9283 21 
in adults and children with no apparent bias (Figure 1). There was good agreement between the 22 
observed concentrations and model predictions for children throughout different weight categories 23 
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(Supplementary Figure 3). The VPCs revealed good agreement between the model simulations 1 
and the 5th, 50th and 95th percentiles of the observations and the model adequately described the 2 
time-course of AT9283 concentrations (Figure 2).  The simulated prediction intervals for children 3 
post-infusion are wide due to the lack of data collected after 80 hours. All parameters were 4 
estimated with acceptable precision (residual standard error <30%), without any significant 5 
shrinkage (<30%) and the non-parametric bootstrap indicated that the model was robust (Table 3). 6 
 7 
3.3 AT9283 exposure 8 
 9 
AT9283 exposure at the MTD was investigated using the median covariate values of each 10 
population group (Table 4, Figure 3). In the solid tumor studies, the MTD was 27 mg/m2/72h for 11 
adults and 55.5 mg/m2/72h for children. Using the median BSA, these doses are equivalent to 12 
median doses of 51 mg/72h and 68 mg/72 h, in adults and children, respectively. The median 13 
MTD in adults with leukaemia was 10-fold higher (567 mg/72h) than for patients with solid 14 
tumours, with a median 𝐴𝑈𝐶9T` of 20, 956 h.ng/mL (4,774– 76,805 h.ng/mL, range).  15 
Children with leukaemia (median weight 16 kg) only reached an 𝐴𝑈𝐶9T` of 2,949 h.ng/mL (539 16 
– 9,988 h.ng/mL, range) at the median maximum dose administered (51 mg/72h). To reach an 17 
MTD drug exposure comparable to that in adults with leukaemia, children with leukaemia would 18 
require doses of 500 mg/72 h, to achieve an 𝐴𝑈𝐶9T` of 38,254 h.ng/mL (9694 – 124,430 19 
h.ng/mL) (Figure 3). To account for the range of weights in children, doses of 30 mg/kg/72 h 20 
would provide a more consistent exposure in children rather than a flat dose of 500 mg/72 h 21 
(Supplementary Figure 4). Figure 4 shows the differences in the drug exposure with varying 22 
GFR and weight at a dose of 30 mg/kg/72 h. A weight-based dosing regimen reduced the 23 
13 
 
variability in the drug exposure for children, whilst the effect of GFR would be significant only 1 
for patients with poor kidney function. 2 
 3 
 4 
4. DISCUSSION 5 
 6 
The primary objective of oncology Phase I dose-finding studies is to determine the MTD and the 7 
dose level below the MTD is usually carried forward to Phase II oncology trials [23, 24]. However, 8 
there are numerous issues that may prevent the completion of Phase I oncology trials. Firstly, the 9 
recruitment rate may be slow because only patients who are resistant to standard treatment are 10 
eligible. Secondly, Phase I oncology trials have a long dose-escalation scheme, with initial doses 11 
far below the MTD to minimize toxicity, which consequently increases the number of patients 12 
treated at sub-therapeutic doses. In the case of the AT9283 trial in children with leukaemia, the 13 
lowest target inhibitory dose was used as the starting dose due to some concerns with cardiotoxicity 14 
in the adult studies [8]. However, the combination of slow recruitment with a coincident increase 15 
in competing studies and long dose-escalation scheme eventually led to the termination of the trial. 16 
The population pharmacokinetic approach was therefore used to estimate what the MTD would be 17 
for children with leukaemia. One of the main advantages of using the population approach is that 18 
the data from adults and children can be combined to provide robust estimates of the 19 
pharmacokinetics of AT9283 (Figure 1 and 2). 20 
The adult and child datasets were combined by adjusting all pharmacokinetic parameters 21 
for body weight. Compared to BSA, the inclusion of body weight as a covariate provided the 22 
largest drop in OFV. Body weight is also the preferred covariate for body size because it is 23 
14 
 
directly measurable and estimating BSA for small children is difficult [25]. Furthermore, renal 1 
function as estimated by GFR, was found to be a significant covariate for CL, consistent with the 2 
finding that 20-30% of the drug is eliminated in the urine [7].  3 
The absolute MTD administered to adults and children with solid tumours were similar, 4 
after accounting for the differences in BSA. Previous studies have reported a much higher MTD 5 
for children with solid tumours (55.5 mg/m2/72h) [4] compared to adults with solid tumors (27 6 
mg/m2/72h) [7], which corresponded to mean absolute doses of 67.7 mg/72 h and 51.3 mg/72h in 7 
children and adults, respectively. Children with solid tumors had an approximately 25% higher 8 
AUC compared to adults with solid tumors (Figure 3, Supplementary Figure 2). Considering that 9 
most responses occur within 80% and 120% of the MTD [23, 24, 26], the potential MTD dose 10 
range in adults with solid tumors (41 to 61.6 mg/72 h, range) is comparable to the MTD dose 11 
range in children with solid tumors (54.2 to 81.2 mg/72 h).  12 
 13 
The main dose limiting toxicity (DLT) of AT9283 was febrile neutropaenia [7], therefore 14 
patients with leukaemia can tolerate much higher doses of AT9283. In adults with leukaemia the 15 
MTD (567 mg/72 h) resulted in a 10-fold higher drug exposure (median 𝐴𝑈𝐶9T`: 20, 956 16 
h.ng/mL; range, 4,774 – 76, 805 h.ng/mL) compared to adults with solid tumors (Figure 3). To 17 
achieve this same level of exposure, we estimated that the MTD would need to be 10-fold higher 18 
than the maximum dose administered to children with leukaemia. We have found that doses of 19 
30 mg/kg/72 h are suitable for children to obtain a similar drug exposure to that see in adults 20 
with leukaemia at the MTD. 21 
The AUC of AT9283 is higher for patients with poor kidney function and for patients 22 
with large body size (Figure 4). Since children enrolled in the Phase I studies have predominately 23 
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normal kidney function, GFR was a more relevant predictor of AT9283 exposure in adults (GFR 1 
77.1 [31.9 – 170.5] mL/min/1.73m2). In contrast, body weight is a more relevant predictor of 2 
drug exposure in children, particularly for children at the extremes of body weight (Figure 4).  3 
 4 
A limitation of this study is the small sample size in children with leukaemia (n = 7). 5 
Children with leukaemia were also the youngest population group and had the smallest body 6 
size. Since there is limited data on very young children, large variability in the concentrations of 7 
AT9283 was observed in our simulations of children with leukaemia (Figure 3).  8 
 9 
We have provided an estimate of the MTD in children with leukaemia, which is based on 10 
achieving a target AUC. However, the identified MTD in Phase I studies was based on the 11 
incidence of DLTs at discrete dosing levels. The MTD represents the dose for which the 12 
percentage experiencing the DLT ranges from 15% to 70%, which may differ significantly from 13 
the actual MTD [27]. Since Phase I oncology studies only assessed the toxicity profile of 14 
anticancer drugs, it is not known how the MTD relates to the efficacy of AT9283. Knowledge of 15 
the exposure-response relationship of AT9283 would provide a better indication of the target 16 
AUC required to achieve an optimal response. 17 
 18 
4.1 Conclusions 19 
The population pharmacokinetic analysis provides a method of shortening the time to reach the 20 
MTD by potentially reducing the number of patients enrolled in dose-escalation trials and the 21 
number of patients treated at sub-therapeutic doses. We have found weight to be a better 22 
predictor of the pharmacokinetics of AT9283 rather than BSA for children, whilst GFR is a 23 
16 
 
relevant predictor of CL, for adults.  If the Phase I trial was to be completed in children with 1 
leukaemia, we estimated that the MTD for children with leukaemia would be 30 mg/kg/72 h, 2 
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Figure Legends 1 
 2 
Figure 1. Goodness-of-fit plots of the final model. The open circles are the observations from the 3 
adult dataset and the open triangles are the observations from the children. The population 4 
prediction and individual prediction plots are shown with the line of identity (black) and a linear 5 
regression line (blue). Plots of CWRES are shown with a loess smooth (blue line). CWRES, 6 
conditional weighted residuals. 7 
 8 
Figure 2. Prediction-corrected visual predictive checks (VPCs) of the AT9283 concentrations 9 
stratified by population. The dots are the observations plotted with the median observed AT9283 10 
concentrations (red line) and the 5th and 95th percentiles of the observed concentrations (dotted 11 
blue lines). The shaded areas are the 95% confidence intervals of the 5th, 50th and 95th percentiles 12 
of the simulated concentrations. 13 
 14 
Figure 3. Simulations of AT9283 exposure at the MTD in (a) adults with solid tumours, (b) 15 
adults with leukaemia, (c) children with solid tumors, (d) and the estimated MTD in children 16 
with leukaemia (500 mg/72h). The black solid lines are the median AT9283 concentrations and 17 
the shaded areas are the 90% prediction intervals of the simulations. 18 
 19 
Figure 4. Simulated median AT9283 concentrations at a dose of 30/kg/72 h over a range of GFR 20 
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Figure 3. Simulations of AT9283 exposure at the MTD in (a) adults with solid tumours, (b) adults with 
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mg/72h). The black solid lines are the median AT9283 concentrations and the shaded areas are the 90% 
prediction intervals of the simulations. 
 
  
Figure 4. Simulated median AT9283 concentrations at a dose of 30/kg/72 h over a range of GFR and 








Table 1. The study design of Phase I clinical trials of AT9283. 
 
Study Arkenau et al. 2012 Foran et al. 2014 Moreno et al. 2015 Cancer Research UK  
Trial Identifier NCT00443976 NCT00522990 NCT00985868 NCT00522990 
Population Adults Adults Children Children (6 months to 18 
years) 
Cancer Solid tumors Relapsed or refractory 
leukaemias 
Solid tumors Relapsed or refractory 
acute leukaemias 
Recruitment period 2006 – 2009 2006 – 2009 2009 - 2012 2011 - 2014 
Study Design 3+3 3+3 Rolling six 3+3 
Doses (mg/m2/72h) 4.5 to 36  9 to 486  21– 66  27– 69  
Blood time-points  
(h after dose) 
0.5, 1, 4, 8, 12, 22, 32, 
46, 56, 70, 72, 72.05, 
72.25, 72.30, 72.45, 73, 
74, 75, 76, 78, 80, 84, 96 
h and day 8 in cycles 1 
and 2. 
0.5, 1, 4, 8, 12, 22, 32, 
46, 56, 70, 72, 72.05, 
72.25, 72.30, 72.45, 73, 
74, 75, 76, 78, 80, 84, 96 
h and day 8 in cycles 1 
and 2. 
0, 4, 24, 48, 70, 73, 76 
and 96 h after the start 
of the infusion cycle 
1. 
0, 4, 24, 48, 70, 73, 76 and 
96 h after the start of the 
infusion cycle 1. 
Identified MTD 
(mg/m2/72h) 
27 324 55.5 - 
Table 2. Demographics of subjects enrolled in Phase I trials. Values are median (range). 
 Astex Pharmaceuticals Cancer Research UK 
Population Adults Children 
Cancer Solid tumour Leukaemia Solid tumour Leukaemia 




(4.5 – 36) 
36 
(9 – 486) 
39 
(21 – 69) 
43.5 




(34 – 77) 
54 
(22 – 86) 
9 
(3 – 18) 
3 




(48.7 – 120.5) 
67.4 
(41.9 – 114) 
29.2 
(12.6 – 62.5) 
16.1 




(1.50 – 2.50) 
1.78 
(1.32 – 2.41) 
1.02 
(0.56 – 1.69) 
0.68 




(14.9 – 34.9) 
23.9 
(17.2 – 43.6) 
17.0 
(14.1 – 24.1) 
16.8 




(51.4 – 125.7) 
78.9 
(31.9 – 170.5) 
125.5 
(47.4 – 229.2) 
154.3 




 Table 3. Final population parameter estimates from the final model. IIV, inter-individual 
variability (%), RSE, residual standard error.  




CL (L/h/70kg) 32.3 (5) 32.2 (30.0 – 34.9) 
VC (L/70kg) 58.6 (7) 58.5 (50.1 – 64.9) 
Q (L/h/70kg) 38.5 (12) 39.2 (32.5 – 49.2) 
VP (L/70kg) 162 (6) 162 (148.3 – 179.5) 
GFR exponent 0.453 (23) 0.452 (0.206 – 0.606) 
IIV (%)   
ηCL 42.9 (9) 43.1 (36.2 – 49.6) 
ηVC 29.8 (17)  30.5 (22.0 – 40.8) 
ηQ 77 (18) 74.1 (44.5 – 98.7) 
  ηVP 38.9 (13) 38.6 (30.4 – 47.7) 
Residual errors   
Adults   
Additive (ng/mL) 0.166 (6) 0.163 (0.145 – 0.181) 
   Proportional (%) 49.9 (24) 50.0 (28.1 – 75.8) 
 Children   
   Additive (ng/mL) 0.359 (8) 0.359 (0.308 – 0.409) 
 
  
Table 4. Model-derived AUC for each group at the MTD. Values are median (range). 
 








BSA (m2) 1.9 1.75 1.22 0.74 
GFR 
(mL/min/1.73m2) 
79 77 117 154 
MTD dose 
(mg/72h) 
51.3 567 67.7 500* 
AUC (h.ng/mL) 1653 
(364 – 6307) 
20,956  
(4774 – 76,805) 
2984 
(681 – 14220) 
38,254 
(9694 – 124,430) 
*Simulated MTD for children with leukaemia. 





Supplementary Figure 2. The simulated distribution of AUC at the maximum tolerated dose. For 







Supplementary Figure 3. The observed concentrations plotted against population predicted 
concentrations and individual predicted concentrations, stratified by weight. 
 
  
Supplementary Figure 4. Model-derived AUC for flat dosing of 500 mg/72 h vs weight-based 
dosing of 30 mg/kg/72 for children at varying weights 
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